By a modified Delphi approach, the present study identifies the most debated topics in HR+/HER2- MBC setting, quantifies the level of discordance or agreement among oncologists dedicated to breast cancer and oncologists not dedicated to breast cancer specifically, and finally tries to draw reasonable guidelines mainly based on expert opinion and everyday practice. Here, ERBB2 is linked to breast carcinoma.